Diabetes: Insulet and Dexcom call it quits on development agreement

Broken handshake illustration

Diabetes technology makers Insulet (NSDQ:PODD) and  (NSDQ:DXCM) abandoned a 5-year-old joint development deal that would have merged Dexcom’s continuous glucose monitoring technology with Insulet’s OmniPod insulin delivery system, officials confirmed with MassDevice.com today.

The pair parted ways over differences in their vision for the future of diabetes management technology. Each wants to lower the quantity of devices a diabetic patient must carry in order to manage the disease, but are pursuing diverging avenues for integrating existing monitoring and treatment technologies.

Insulet aims to reduce the number of skin-worn devices while Dexcom is looking to shift its monitoring systems onto the smartphones that patients already have in their pockets.

Insulet’s already moved on to the next potential partner, an unnamed private company with technology that aims to allow OmniPod technology to deliver insulin and gather continuous blood glucose data through a single site rather than through 2 devices attached to the skin.

Insulet had hinted at the change in direction earlier this year when presenting at the J.P. Morgan conference in San Francisco.

"We think we can put 1 thing on the body, that will sense and deliver insulin all in the same space," DeSisto told the J.P. Morgan audience. "People want 1 thing on the body."

Insulet CFO Brian Roberts reiterated those sentiments in an email conversation with MassDevice.com today. One of the largest barriers to adoption of diabetes management technologies, Roberts told us, is the need to wear multiple items on the body all day, every day.

"Research that we have completed suggests that while more than 90% of people living with insulin dependent diabetes are willing to wear 1 thing on their body 24/7, that the number drops below half when people are asked if they’re willing to continuously wear 2 items on the body," Roberts said. "We’re focusing our time and efforts on what we believe to be the best solution for a person living with insulin dependent diabetes, a solution where the CGM sensor is contained within the OmniPod, thus providing an answer of only one thing on the body and one device in hand."

The development deal with Dexcom would have pared down the hand-held systems from 2 to 1, but the CGM sensor would have remained separate from the infusion site. An all-in-1 technology does not yet exist, which may mean that the regulatory pathway for a true 2-in-1 technology may mean blazing a new trail through the FDA, Diabetes Mine reported.

Insulet’s eying a combined CGM/infusion system that will gather data and deliver insulin through a single hand-held device and using a single transmitter/sensor site on the body. Other combination devices in development are similar to that proposed in the now-defunct Dexcom/Insulet R&D agreement; they aim to merge monitoring and treatment software into a single hand-held device but still require separate transmitters and infusion sites on the body, Roberts noted.

CEO Duane DeSisto told investors last month that it had joined forces with a new CGM partner and that it hoped to sign a formal agreement in short order to further pursue its all-in-one technology. Roberts said today that the company "believes" it has a partner in place to develop a "truly integrated pump/CGM solution."

Dexcom is moving forward with its next-generation CGM sensor, which transmits directly to a smartphone rather than working through an independent hand-held system. Dexcom CEO Terry Gregg showed off the Gen 5 CGM at the 2013 International CES in Las Vegas late last month, where he showed reporters an smartphone app that was connected to a continuous glucose monitor he was wearing on his own skin. The app shows real-time data and trends for up to 24 hours and can send texts to caregivers if the glucose levels were outside of safe ranges, Gregg said.

"What Dexcom has clearly stated is that they want to basically have their CGM go directly to a phone," DeSisto told the J.P. Morgan audience. "Well, if it’s going to go directly to a phone I’m not going to spend a year, year-and-a-half, integrating that into our particular product."

The integration of Dexcom and Insulet technology into a single hand-held system became "redundant" when Dexcom decided to pursue smartphone technology, Insulet’s Roberts told us.

"While we would have enjoyed the opportunity to continue to work with Dexcom to see if their sensor would have met the technical requirements necessary for integration into our OmniPod, that was not something that they were interested in doing at this time," Roberts said.

Representatives for Dexcom did not respond to requests for comment.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply